Blog Posts
FDA
Photo from Prime Medicine/X

FDA has cleared Prime Medicine’s PM359 for the treatment of chronic granulomatous disease

Prime Medicine shared on X/Twitter:

“We are pleased to announce that FDA has cleared our IND application for PM359 for the treatment of chronic granulomatous disease (CGD), enabling Prime to initiate its Phase 1/2 clinical trial in the US. Details.”

Source: Prime Medicine/X

cancer chronic granulomatous disease clinical trial FDA OncoDaily Oncology PM359 Prime Medicine